Your browser doesn't support javascript.
loading
Residual homing of α4ß7-expressing ß1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.
Becker, Emily; Dedden, Mark; Gall, Christine; Wiendl, Maximilian; Ekici, Arif Bülent; Schulz-Kuhnt, Anja; Schweda, Anna; Voskens, Caroline; Hegazy, Ahmed; Vitali, Francesco; Atreya, Raja; Müller, Tanja Martina; Atreya, Imke; Neurath, Markus F; Zundler, Sebastian.
Afiliación
  • Becker E; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Dedden M; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Gall C; Institute for Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Wiendl M; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Ekici AB; Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Schulz-Kuhnt A; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Schweda A; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Voskens C; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Hegazy A; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Bayern, Germany.
  • Vitali F; Department of Gastroenterology, Infectiology and Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Berlin, Germany.
  • Atreya R; Berlin Institute of Health (BIH), Berlin, Germany.
  • Müller TM; Deutsches Rheumaforschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  • Atreya I; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Neurath MF; Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg, Erlangen, Bayern, Germany.
  • Zundler S; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Bayern, Germany.
Gut ; 71(8): 1551-1566, 2022 08.
Article en En | MEDLINE | ID: mdl-34462337
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Enfermedades Inflamatorias del Intestino Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Enfermedades Inflamatorias del Intestino Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article País de afiliación: Alemania